Standard Standard

HarvardHarvard

Sivaprasad, S, Hykin, P, Prevost, AT, Vasconcelos, J, Riddell, A, Ramu, J, Murphy, C, Kelly, J, Edwards, R, Yeo, ST, Bainbridge, J, Hopkins, D & White-Alao, B 2018, Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY): a noninferiority randomised trial. NIHR.

APA

Sivaprasad, S., Hykin, P., Prevost, A. T., Vasconcelos, J., Riddell, A., Ramu, J., Murphy, C., Kelly, J., Edwards, R., Yeo, S. T., Bainbridge, J., Hopkins, D., & White-Alao, B. (2018). Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY): a noninferiority randomised trial. NIHR.

CBE

MLA

VancouverVancouver

Author

RIS

TY - BOOK

T1 - Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY)

T2 - a noninferiority randomised trial

AU - Sivaprasad, S

AU - Hykin, P

AU - Prevost, A.T.

AU - Vasconcelos, J

AU - Riddell, A

AU - Ramu, J

AU - Murphy, C

AU - Kelly, J

AU - Edwards, Rhiannon

AU - Yeo, Seow Tien

AU - Bainbridge, J

AU - Hopkins, D

AU - White-Alao, B

PY - 2018/1

Y1 - 2018/1

N2 - NIHR Efficacy and Mechanistic Evaluation (EME) Programme Report

AB - NIHR Efficacy and Mechanistic Evaluation (EME) Programme Report

M3 - Commissioned report

BT - Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY)

PB - NIHR

ER -